BofA Merrill Lynch, Jefferies are joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., Sept. 26 - Enzymotec Ltd. said it priced its $61.77 million initial public offering of stock with a $9.27 million greenshoe. The deal was announced Aug. 22.
The company will sell 4,412,000 ordinary shares at $14.00 per share.
BofA Merrill Lynch and Jefferies LLC are the joint bookrunning managers.
Settlement is expected Oct. 2.
Proceeds will be used for working capital requirements and other general corporate purposes.
The nutritional ingredients and medical foods company is based in Migdal Ha'Emeq, Israel. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "ENZY."
| Issuer: | Enzymotec Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | $61,768,000
|
| Greenshoe: | $9,265,200
|
| Shares: | 4,412,000
|
| Price: | $14.00
|
| Warrants: | No
|
| Bookrunners: | BofA Merrill Lynch and Jefferies LLC
|
| Lead manager: | Wells Fargo Securities, LLC
|
| Co-managers: | Canaccord Genuity and Wedbush Securities
|
| Announcement date: | Aug. 22
|
| Pricing date: | Sept. 26
|
| Settlement date: | Oct. 2
|
| Stock exchange: | Nasdaq: ENZY
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
